A Phase 3 interventional study of Placebo and Ravulizumab in Chronic Kidney Disease, CKD and Cardiac Disease, sponsored by Alexion Pharmaceuticals, Inc.. Terminated at 130 sites in 20 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Renal Insufficiency, Chronic by AstraZeneca — 6 open to participants now, 11 under way, 5 of them phase 3. Renal Insufficiency, Chronic · AstraZeneca.
Among the 54 studies in Renal Insufficiency, Chronic by AstraZeneca, this one is the 12th largest by enrollment of the 38 interventional ones that give a count, is one of 5 that started in 2023, is one of 10 in phase 3, and was the 31st registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →6 of the 54 studies in Renal Insufficiency, Chronic by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 24 more countries
Ages 18–99
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 18+
AstraZeneca · Sites in China
AstraZeneca · Sites in United States
Ages 18–75 · Healthy volunteers
AstraZeneca · Sites in United States, Argentina, Australia and 39 more countries
Ages 18+
By country, each count listing its studies:
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 555 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 170 across the 38 interventional studies, 4,000 across the 16 observational. Of the 43 that completed or were terminated, 18 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
3 of the studies in Renal Insufficiency, Chronic by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07222917AstraZenecaA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | 2026-12-10 |
| NCT07024823AstraZenecaA Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes, Assess Home Measurements of Creatinine in a Non-Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants | 2027-01-29 |
| NCT06610526AstraZenecaA Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease | 2027-05-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies in Renal Insufficiency, Chronic by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive a single weight-based dose of placebo via intravenous infusion, 1 to 7 days prior to surgery.
Drug: Placebo
Participants will receive a single weight-based dose of ravulizumab, via intravenous infusion, 1 to 7 days prior to surgery.
Drug: Ravulizumab
Participants will receive a single weight-based dose of placebo via intravenous infusion.
Participants will receive a single weight-based dose of ravulizumab via intravenous infusion.
Estimated Percentage of Participants Who Experienced Major Adverse Kidney Events (MAKE, Based on Serum Cystatin C [sCysC)] at Day 90 Post-CPB (MAKE90)
MAKE90 was defined as meeting at least one of the following three criteria: * Decrease from baseline in estimated glomerular filtration rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula using sCysC) of ≥ 25% at Day 90 post CPB, * Initiation of kidney replacement therapy (KRT) through Day 90 post CPB, or * Death from any cause through Day 90 post CPB. Estimated percentages were calculated using imputation of missing data. Missing data for KRT initiation or death were imputed as non-events. Missing eGFR values were addressed using a two-step multiple imputation approach under the assumption of missing at random (MAR).
Time frame: Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Estimated Percentage of Participants With Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) Without Recovery at Day 90 Post-CPB
CSA-AKI without recovery was defined as experiencing CSA-AKI based on highest observed serum creatinine (sCr) from randomization to Day 7 post CPB and had occurrence of non-recovered (complete \[sCr \< 1.1\*baseline\] or partial \[sCr ≥ 1.1 to \< 1.5\*baseline\]) CSA-AKI at Day 90. The occurrence of post-operative CSA-AKI was defined as the presence of one of the following two observations during the 7 days after surgery with CPB, based on the modified Kidney Disease: Improving Global Outcomes (nonprofit foundation, KDIGO) criteria: * An increase in sCr by ≥ 0.3 milligrams per deciliter (mg/dL) in a 48-hour period, or * An increase in sCr to ≥ 1.5\*baseline within the 7 days following CPB. Estimated percentages were calculated using imputation of missing data. Missing values were imputed as non-events.
Time frame: Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Estimated Percentage of Participants With Severe CSA-AKI (KDIGO Stage 2 or 3)
Occurrence of severe CSA-AKI from randomization to Day 7 and Day 30 post-CPB was defined as meeting KDIGO stage 2 or 3 based on the highest observed sCr from randomization to Day 7 and Day 30 post-CPB. Estimated percentages were calculated using imputation of missing data. Missing values were imputed as non-events. CSA-AKI Staging by Modified KDIGO Criteria: * AKI Stage 1 - An increase in sCr by ≥ 0.3 mg/dL in a 48-hour period, or an increase in sCr to ≥ 1.5 to \< 2.0\*baseline. * AKI Stage 2 - An increase in sCr to ≥ 2.0 to \< 3.0\*baseline. * AKI Stage 3 - An increase in sCr to ≥ 3.0\*baseline, or an increase in sCr to ≥ 4.0 mg/dL in participants meeting AKI criteria, or initiation of KRT.
Time frame: From randomization to Days 7 and 30 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Estimated Percentage of Participants Who Died or Required KRT From Randomization to Day 90 Post-CPB
Estimated percentages were calculated using imputation of missing data. Missing data for the death component were addressed using a multiple imputation approach under the assumption of MAR. Missing values for the KRT component were imputed as non-events.
Time frame: From randomization to Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Estimated All-cause Mortality From Randomization to Day 90 Post-CPB
Estimated all-cause mortality data (estimated percentage of participants who died) from randomization to Day 90 post-CPB is reported in this outcome measure. Estimated percentages were calculated using imputation of missing data. Missing data for death were addressed using a multiple imputation approach under the assumption of MAR. A summary of all-cause mortality through to the end of the study, without imputation for missing data, is located in the 'Reported Adverse Events' Section.
Time frame: From randomization to Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Estimated Median Length of Post-operative Intensive Care Unit (ICU) Stay
The length of post-operative ICU stay was calculated based on the date/time of post-operative ICU discharge - the date/time of post-operative ICU admission for a participant who was admitted to ICU post-surgery and was alive at ICU discharge. Estimated medians were calculated using imputation of missing data. Missing length of post-operative ICU stay was imputed by the worst value due to death and median of all participants due to other reasons.
Time frame: From randomization to Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Estimated Percentage of Participants Who Experienced MAKE at Day 30 (MAKE30) and Day 60 (MAKE60) Post-CPB Based on sCysC
MAKE30 and MAKE60 were defined as meeting at least one of the following criteria: * Decrease from baseline in eGFR (CKD-EPI formula using sCysC) of ≥ 25% at Day 30 or 60 post CPB, * Initiation of KRT through Days 30 or 60 post CPB, or * Death from any cause through Days 30 or 60 post CPB. Estimated percentages were calculated using imputation of missing data. Missing data for KRT initiation or death were imputed as non-events. Missing eGFR values were addressed using a two-step multiple imputation approach under the assumption of MAR.
Time frame: Days 30 and 60 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Estimated Percentage of Participants Who Experienced MAKE30, MAKE60, and MAKE90 Post-CPB Based on sCr
MAKE30, MAKE60 and MAKE90 were defined as meeting at least one of the following three criteria: * Decrease from baseline in eGFR (CKD-EPI formula using sCr) of ≥ 25% at Days 30, 60, or 90 post CPB, * Initiation of KRT through Days 30, 60, or 90 post CPB, or * Death from any cause through Days 30, 60, or 90 post CPB. Estimated percentages were calculated using imputation of missing data. Missing data for KRT initiation or death were imputed as non-events. Missing eGFR values were addressed using a two-step multiple imputation approach under the assumption of MAR.
Time frame: Days 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
MAKE Components: Estimated Percentage of Participants Who Died From Randomization Through Days 30, 60, and 90
The estimated percentage of participants who died from any cause from randomization through Days 30, 60, or 90 are reported. Note that data imputation for this outcome measure is different than the imputation for the 'All-cause Mortality' outcome measure. Missing data for this outcome measure were imputed as non-events. A summary of all-cause mortality through to the end of the study, without imputation for missing data, is located in the 'Reported Adverse Events' Section.
Time frame: From randomization to Days 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
MAKE Components: Estimated Percentage of Participants With Initiation of KRT
Estimated percentage of participants with initiation of KRT through Days 30, 60, or 90 post-CPB are reported. Estimated percentages were calculated using imputation of missing data. Missing data were imputed as non-events.
Time frame: From randomization to Days 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
MAKE Components: Estimated Percentage of Participants With Decrease From Baseline in eGFR of ≥ 25% Based on sCysC
Estimated percentage of participants with a decrease from baseline in eGFR (CKD-EPI formula using sCysC) of ≥ 25% at Days 30 or 60 post-CPB is reported. Estimated percentages were calculated using imputation of missing data. Missing eGFR values were addressed using a two-step multiple imputation approach under the assumption of MAR.
Time frame: Baseline to Days 30 and 60 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
MAKE Components: Estimated Percentage of Participants With Decrease From Baseline in eGFR of ≥ 25% Based on sCr
Estimated percentage of participants with a decrease from baseline in eGFR (CKD-EPI formula using sCr) of ≥ 25% at Days 30, 60, or 90 post-CPB is reported. Estimated percentages were calculated using imputation of missing data. Missing eGFR values were addressed using a two-step multiple imputation approach under the assumption of MAR.
Time frame: Baseline to Days 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Estimated Percentage of Participants Who Died or Required KRT From Randomization to Days 30 and 60 Post-CPB
Estimated percentages were calculated using imputation of missing data. Missing data for KRT initiation or death were imputed as non-events.
Time frame: From randomization to Days 30 and 60 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Estimated Percentage of Participants With Post-Operative Renal Failure
Post-operative renal failure was a Society of Thoracic Surgeons (STS) metric based on modified Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE) failure creatinine criteria and was defined as: * An increase in sCr to ≥ 3.0\*baseline, * An increase in sCr to ≥ 4.0 mg/dL with an increase of at least 0.5 mg/dL from baseline, or * Initiation of KRT. Estimated percentages were calculated using imputation of missing data. Missing values were imputed as non-events.
Time frame: From randomization to Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Number of Participants With Highest CSA-AKI Stage (Modified KDIGO Criteria) Based on sCr
The occurrence of post-operative CSA-AKI was defined as the presence of one of the following two observations during the 3 or 7 days after surgery with CPB, based on the modified KDIGO criteria: * An increase in sCr by ≥ 0.3 mg/dL in a 48-hour period, or * An increase in sCr to ≥ 1.5\*baseline within the 7 days following CPB. CSA-AKI Staging by Modified KDIGO Criteria: * AKI Stage 1 - An increase in sCr by ≥ 0.3 mg/dL in a 48-hour period, or an increase in sCr to ≥ 1.5 to \< 2.0\*baseline. * AKI Stage 2 - An increase in sCr to ≥ 2.0 to \< 3.0\*baseline. * AKI Stage 3 - An increase in sCr to ≥ 3.0\*baseline, or an increase in sCr to ≥ 4.0 mg/dL in participants meeting AKI criteria, or initiation of KRT.
Time frame: Within 3 and 7 Days Post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Estimated Percentage of Participants With CSA-AKI Without Recovery at Days 15, 30, and 60 Post-CPB
CSA-AKI without recovery was defined as experiencing CSA-AKI based on highest observed sCr from randomization to Day 7 post CPB and had occurrence of non-recovered (complete \[sCr \< 1.1\*baseline\] or partial \[sCr ≥ 1.1 to \< 1.5\*baseline\]) CSA-AKI at Days 15, 30, or 60. The occurrence of post-operative CSA-AKI was defined as the presence of one of the following two observations during the 7 days after surgery with CPB, based on the KDIGO criteria: * An increase in sCr by ≥ 0.3 milligrams per deciliter (mg/dL) in a 48-hour period, or * An increase in sCr to ≥ 1.5\*baseline within the 7 days following CPB. Estimated percentages were calculated using imputation of missing data. Missing values were imputed as non-events.
Time frame: Days 15, 30, and 60 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Estimated Percentage of Participants With AKI at Days 3, 7, 15, 30, 60, and 90 Post-CPB
AKI was defined as sCr \> 1.5\*baseline at Days 3, 7, 15, 30, 60, and 90 post-CPB. Estimated percentages were calculated using imputation of missing data. Missing values were imputed as non-events.
Time frame: Days 3, 7, 15, 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Number of Participants With AKI Progression on Days 15, 30, 60, and 90 Post-CPB for Those Experiencing CSA-AKI Within 7 Days Post-CPB
Occurrence of post-operative CSA-AKI was using modified KDIGO criteria within 7 days after CPB: An increase in sCr by ≥0.3 mg/dL in a 48-hour period or ≥1.5\*baseline within the 7 days following CPB. Stages of post-CSA-AKI kidney function to determine AKI progression: * Post-AKI stage 0 - Complete recovery: sCr \<1.1\*baseline or partial recovery: sCr ≥1.1 to \<1.5 × baseline; * Post-AKI Stage 1 - sCr ≥1.5 to \<2.0\*baseline; * Post-AKI Stage 2 - sCr ≥2.0 - \<3.0\*baseline; * Post-AKI Stage 3 - sCr ≥3.0\*baseline, or sCr ≥4.0 mg/dL in participants meeting CSA-AKI criteria or KRT. AKI progression: * AKI recovery - Complete: sCr \<1.1\*baseline or Partial: sCr ≥1.1 - \<1.5\*baseline * AKI improvement - Move down 1 or more stages from the highest CSA-AKI stage, or remained in stage 3 but discontinued KRT; * Stable AKI - Unchanged AKI or KRT status; * Worsening AKI - Moved up 1 or more stages from the highest CSA-AKI stage, or Remained in Stage 3 but initiated KRT.
Time frame: Days 15, 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
| Milestone | Ravulizumab | Placebo |
|---|---|---|
| Started | 278 | 277 |
| Received at least 1 dose of study treatment | 276 | 273 |
| Completed | 231 | 251 |
| Not completed | 47 | 26 |
| Withdrew: Withdrawal by subject | 10 | 6 |
| Withdrew: Death | 33 | 20 |
| Withdrew: Other than specified | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Milestone | Ravulizumab | Placebo |
|---|---|---|
| Started | 235 | 251 |
| Completed | 153 | 153 |
| Not completed | 82 | 98 |
| Withdrew: Study termination | 82 | 98 |
MAKE90 was defined as meeting at least one of the following three criteria: * Decrease from baseline in estimated glomerular filtration rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula using sCysC) of ≥ 25% at Day 90 post CPB, * Initiation of kidney replacement therapy (KRT) through Day 90 post CPB, or * Death from any cause through Day 90 post CPB. Estimated percentages were calculated using imputation of missing data. Missing data for KRT initiation or death were imputed as non-events. Missing eGFR values were addressed using a two-step multiple imputation approach under the assumption of missing at random (MAR).
| percentage of participants | Ravulizumab | Placebo |
|---|---|---|
| Estimated Percentage of Participants Who Experienced Major Adverse Kidney Events (MAKE, Based on Serum Cystatin C [sCysC)] at Day 90 Post-CPB (MAKE90) | 35.0 | 33.2 |
CSA-AKI without recovery was defined as experiencing CSA-AKI based on highest observed serum creatinine (sCr) from randomization to Day 7 post CPB and had occurrence of non-recovered (complete \[sCr \< 1.1\*baseline\] or partial \[sCr ≥ 1.1 to \< 1.5\*baseline\]) CSA-AKI at Day 90. The occurrence of post-operative CSA-AKI was defined as the presence of one of the following two observations during the 7 days after surgery with CPB, based on the modified Kidney Disease: Improving Global Outcomes (nonprofit foundation, KDIGO) criteria: * An increase in sCr by ≥ 0.3 milligrams per deciliter (mg/dL) in a 48-hour period, or * An increase in sCr to ≥ 1.5\*baseline within the 7 days following CPB. Estimated percentages were calculated using imputation of missing data. Missing values were imputed as non-events.
| percentage of participants | Ravulizumab | Placebo |
|---|---|---|
| Estimated Percentage of Participants With Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) Without Recovery at Day 90 Post-CPB | 2.5 | 2.2 |
Occurrence of severe CSA-AKI from randomization to Day 7 and Day 30 post-CPB was defined as meeting KDIGO stage 2 or 3 based on the highest observed sCr from randomization to Day 7 and Day 30 post-CPB. Estimated percentages were calculated using imputation of missing data. Missing values were imputed as non-events. CSA-AKI Staging by Modified KDIGO Criteria: * AKI Stage 1 - An increase in sCr by ≥ 0.3 mg/dL in a 48-hour period, or an increase in sCr to ≥ 1.5 to \< 2.0\*baseline. * AKI Stage 2 - An increase in sCr to ≥ 2.0 to \< 3.0\*baseline. * AKI Stage 3 - An increase in sCr to ≥ 3.0\*baseline, or an increase in sCr to ≥ 4.0 mg/dL in participants meeting AKI criteria, or initiation of KRT.
| percentage of participants | Ravulizumab | Placebo |
|---|---|---|
| Day 7 Post-CPB | 15.1 | 17.3 |
| Day 30 Post-CPB | 14.7 | 19.5 |
Estimated percentages were calculated using imputation of missing data. Missing data for the death component were addressed using a multiple imputation approach under the assumption of MAR. Missing values for the KRT component were imputed as non-events.
| percentage of participants | Ravulizumab | Placebo |
|---|---|---|
| Estimated Percentage of Participants Who Died or Required KRT From Randomization to Day 90 Post-CPB | 16.2 | 18.9 |
Estimated all-cause mortality data (estimated percentage of participants who died) from randomization to Day 90 post-CPB is reported in this outcome measure. Estimated percentages were calculated using imputation of missing data. Missing data for death were addressed using a multiple imputation approach under the assumption of MAR. A summary of all-cause mortality through to the end of the study, without imputation for missing data, is located in the 'Reported Adverse Events' Section.
| percentage of participants | Ravulizumab | Placebo |
|---|---|---|
| Estimated All-cause Mortality From Randomization to Day 90 Post-CPB | 12.3 | 7.4 |
The length of post-operative ICU stay was calculated based on the date/time of post-operative ICU discharge - the date/time of post-operative ICU admission for a participant who was admitted to ICU post-surgery and was alive at ICU discharge. Estimated medians were calculated using imputation of missing data. Missing length of post-operative ICU stay was imputed by the worst value due to death and median of all participants due to other reasons.
| hours | Ravulizumab | Placebo |
|---|---|---|
| Estimated Median Length of Post-operative Intensive Care Unit (ICU) Stay | 67.700 (27.300 to 123.000) | 75.100 (42.050 to 132.050) |
MAKE30 and MAKE60 were defined as meeting at least one of the following criteria: * Decrease from baseline in eGFR (CKD-EPI formula using sCysC) of ≥ 25% at Day 30 or 60 post CPB, * Initiation of KRT through Days 30 or 60 post CPB, or * Death from any cause through Days 30 or 60 post CPB. Estimated percentages were calculated using imputation of missing data. Missing data for KRT initiation or death were imputed as non-events. Missing eGFR values were addressed using a two-step multiple imputation approach under the assumption of MAR.
| percentage of participants | Ravulizumab | Placebo |
|---|---|---|
| MAKE30 | 32.6 | 33.9 |
| MAKE60 | 30.5 | 31.9 |
MAKE30, MAKE60 and MAKE90 were defined as meeting at least one of the following three criteria: * Decrease from baseline in eGFR (CKD-EPI formula using sCr) of ≥ 25% at Days 30, 60, or 90 post CPB, * Initiation of KRT through Days 30, 60, or 90 post CPB, or * Death from any cause through Days 30, 60, or 90 post CPB. Estimated percentages were calculated using imputation of missing data. Missing data for KRT initiation or death were imputed as non-events. Missing eGFR values were addressed using a two-step multiple imputation approach under the assumption of MAR.
| percentage of participants | Ravulizumab | Placebo |
|---|---|---|
| MAKE30 | 26.7 | 25.0 |
| MAKE60 | 24.0 | 23.9 |
| MAKE90 | 25.6 | 24.8 |
The estimated percentage of participants who died from any cause from randomization through Days 30, 60, or 90 are reported. Note that data imputation for this outcome measure is different than the imputation for the 'All-cause Mortality' outcome measure. Missing data for this outcome measure were imputed as non-events. A summary of all-cause mortality through to the end of the study, without imputation for missing data, is located in the 'Reported Adverse Events' Section.
| percentage of participants | Ravulizumab | Placebo |
|---|---|---|
| Day 30 | 10.1 | 6.2 |
| Day 60 | 11.5 | 6.9 |
| Day 90 | 11.9 | 7.2 |
Estimated percentage of participants with initiation of KRT through Days 30, 60, or 90 post-CPB are reported. Estimated percentages were calculated using imputation of missing data. Missing data were imputed as non-events.
| percentage of participants | Ravulizumab | Placebo |
|---|---|---|
| Day 30 | 10.8 | 14.8 |
| Day 60 | 11.1 | 15.2 |
| Day 90 | 11.1 | 15.2 |
Estimated percentage of participants with a decrease from baseline in eGFR (CKD-EPI formula using sCysC) of ≥ 25% at Days 30 or 60 post-CPB is reported. Estimated percentages were calculated using imputation of missing data. Missing eGFR values were addressed using a two-step multiple imputation approach under the assumption of MAR.
| percentage of participants | Ravulizumab | Placebo |
|---|---|---|
| Day 30 | 23.9 | 24.1 |
| Day 60 | 20.2 | 20.1 |
Estimated percentage of participants with a decrease from baseline in eGFR (CKD-EPI formula using sCr) of ≥ 25% at Days 30, 60, or 90 post-CPB is reported. Estimated percentages were calculated using imputation of missing data. Missing eGFR values were addressed using a two-step multiple imputation approach under the assumption of MAR.
| percentage of participants | Ravulizumab | Placebo |
|---|---|---|
| Day 30 | 17.2 | 11.7 |
| Day 60 | 11.7 | 8.0 |
| Day 90 | 13.1 | 9.9 |
Estimated percentages were calculated using imputation of missing data. Missing data for KRT initiation or death were imputed as non-events.
| percentage of participants | Ravulizumab | Placebo |
|---|---|---|
| Day 30 | 14.4 | 18.1 |
| Day 60 | 15.5 | 18.8 |
Post-operative renal failure was a Society of Thoracic Surgeons (STS) metric based on modified Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE) failure creatinine criteria and was defined as: * An increase in sCr to ≥ 3.0\*baseline, * An increase in sCr to ≥ 4.0 mg/dL with an increase of at least 0.5 mg/dL from baseline, or * Initiation of KRT. Estimated percentages were calculated using imputation of missing data. Missing values were imputed as non-events.
| percentage of participants | Ravulizumab | Placebo |
|---|---|---|
| Estimated Percentage of Participants With Post-Operative Renal Failure | 12.6 | 18.1 |
The occurrence of post-operative CSA-AKI was defined as the presence of one of the following two observations during the 3 or 7 days after surgery with CPB, based on the modified KDIGO criteria: * An increase in sCr by ≥ 0.3 mg/dL in a 48-hour period, or * An increase in sCr to ≥ 1.5\*baseline within the 7 days following CPB. CSA-AKI Staging by Modified KDIGO Criteria: * AKI Stage 1 - An increase in sCr by ≥ 0.3 mg/dL in a 48-hour period, or an increase in sCr to ≥ 1.5 to \< 2.0\*baseline. * AKI Stage 2 - An increase in sCr to ≥ 2.0 to \< 3.0\*baseline. * AKI Stage 3 - An increase in sCr to ≥ 3.0\*baseline, or an increase in sCr to ≥ 4.0 mg/dL in participants meeting AKI criteria, or initiation of KRT.
| Participants | Ravulizumab | Placebo |
|---|---|---|
| Highest CSA-AKI Stage Within 3 Days Post-CPB — Stage 1 | 100 | 110 |
| Highest CSA-AKI Stage Within 3 Days Post-CPB — Stage 2 | 3 | 6 |
| Highest CSA-AKI Stage Within 3 Days Post-CPB — Stage 3 | 30 | 38 |
| Highest CSA-AKI Stage Within 7 Days Post-CPB — Stage 1 | 141 | 148 |
| Highest CSA-AKI Stage Within 7 Days Post-CPB — Stage 2 | 4 | 4 |
| Highest CSA-AKI Stage Within 7 Days Post-CPB — Stage 3 | 38 | 43 |
CSA-AKI without recovery was defined as experiencing CSA-AKI based on highest observed sCr from randomization to Day 7 post CPB and had occurrence of non-recovered (complete \[sCr \< 1.1\*baseline\] or partial \[sCr ≥ 1.1 to \< 1.5\*baseline\]) CSA-AKI at Days 15, 30, or 60. The occurrence of post-operative CSA-AKI was defined as the presence of one of the following two observations during the 7 days after surgery with CPB, based on the KDIGO criteria: * An increase in sCr by ≥ 0.3 milligrams per deciliter (mg/dL) in a 48-hour period, or * An increase in sCr to ≥ 1.5\*baseline within the 7 days following CPB. Estimated percentages were calculated using imputation of missing data. Missing values were imputed as non-events.
| percentage of participants | Ravulizumab | Placebo |
|---|---|---|
| Day 15 | 7.5 | 7.9 |
| Day 30 | 5.0 | 5.1 |
| Day 60 | 1.8 | 1.4 |
AKI was defined as sCr \> 1.5\*baseline at Days 3, 7, 15, 30, 60, and 90 post-CPB. Estimated percentages were calculated using imputation of missing data. Missing values were imputed as non-events.
| percentage of participants | Ravulizumab | Placebo |
|---|---|---|
| Day 3 | 20.9 | 25.3 |
| Day 7 | 10.4 | 10.1 |
| Day 15 | 8.6 | 8.3 |
| Day 30 | 5.7 | 5.4 |
| Day 60 | 2.9 | 1.8 |
| Day 90 | 3.2 | 3.2 |
Occurrence of post-operative CSA-AKI was using modified KDIGO criteria within 7 days after CPB: An increase in sCr by ≥0.3 mg/dL in a 48-hour period or ≥1.5\*baseline within the 7 days following CPB. Stages of post-CSA-AKI kidney function to determine AKI progression: * Post-AKI stage 0 - Complete recovery: sCr \<1.1\*baseline or partial recovery: sCr ≥1.1 to \<1.5 × baseline; * Post-AKI Stage 1 - sCr ≥1.5 to \<2.0\*baseline; * Post-AKI Stage 2 - sCr ≥2.0 - \<3.0\*baseline; * Post-AKI Stage 3 - sCr ≥3.0\*baseline, or sCr ≥4.0 mg/dL in participants meeting CSA-AKI criteria or KRT. AKI progression: * AKI recovery - Complete: sCr \<1.1\*baseline or Partial: sCr ≥1.1 - \<1.5\*baseline * AKI improvement - Move down 1 or more stages from the highest CSA-AKI stage, or remained in stage 3 but discontinued KRT; * Stable AKI - Unchanged AKI or KRT status; * Worsening AKI - Moved up 1 or more stages from the highest CSA-AKI stage, or Remained in Stage 3 but initiated KRT.
| Participants | Ravulizumab | Placebo |
|---|---|---|
| Day 15 — Complete Recovery | 4 | 5 |
| Day 15 — Partial Recovery | 1 | 4 |
| Day 15 — Improvement | 2 | 3 |
| Day 15 — Stable | 142 | 158 |
| Day 15 — Worsening | 5 | 5 |
| Day 30 — Complete Recovery | 6 | 7 |
| Day 30 — Partial Recovery | 0 | 7 |
| Day 30 — Improvement | 0 | 2 |
| Day 30 — Stable | 138 | 151 |
| Day 30 — Worsening | 7 | 5 |
| Day 60 — Complete Recovery | 4 | 10 |
| Day 60 — Partial Recovery | 3 | 5 |
| Day 60 — Improvement | 0 | 1 |
| Day 60 — Stable | 133 | 140 |
| Day 60 — Worsening | 3 | 3 |
| Day 90 — Complete Recovery | 7 | 14 |
| Day 90 — Partial Recovery | 0 | 1 |
| Day 90 — Improvement | 0 | 2 |
| Day 90 — Stable | 126 | 147 |
| Day 90 — Worsening | 1 | 1 |
Collected over All-cause mortality was collected up to a maximum of 15 months post-CPB. Serious and other adverse events were collected until end of Primary Evaluation Period (up to a maximum duration of up to 90 days post-CPB). Surgery with CPB was within 7 days after study drug administration on Day 1.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ravulizumab | 39/278 (14%) | 133/276 (48.2%) | 220/276 (79.7%) |
| Placebo | 29/277 (10.5%) | 141/273 (51.6%) | 229/273 (83.9%) |
| Event | Ravulizumab | Placebo |
|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 18/276 | 20/273 |
| Cardiogenic shockCardiac disorders | 13/276 | 6/273 |
| Pericardial effusionCardiac disorders | 13/276 | 3/273 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 7/276 | 12/273 |
| PneumoniaInfections and infestations | 11/276 | 6/273 |
| Postoperative wound infectionInfections and infestations | 9/276 | 4/273 |
| Cardiac arrestCardiac disorders | 4/276 | 7/273 |
| Cerebrovascular accidentNervous system disorders | 4/276 | 7/273 |
| Cardiac failureCardiac disorders | 7/276 | 6/273 |
| Cardiac failure acuteCardiac disorders | 7/276 | 1/273 |
| Event | Ravulizumab | Placebo |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 54/276 | 49/273 |
| Atrial fibrillationCardiac disorders | 45/276 | 42/273 |
| Acute kidney injuryRenal and urinary disorders | 35/276 | 38/273 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 27/276 | 38/273 |
| Oedema peripheralGeneral disorders | 31/276 | 27/273 |
| HyperkalaemiaMetabolism and nutrition disorders | 17/276 | 30/273 |
| NauseaGastrointestinal disorders | 13/276 | 29/273 |
| HypocalcaemiaMetabolism and nutrition disorders | 26/276 | 28/273 |
| ThrombocytopeniaBlood and lymphatic system disorders | 18/276 | 27/273 |
| DeliriumPsychiatric disorders | 16/276 | 27/273 |
Intent-to-treat (ITT) Analysis Set included all participants randomized to study intervention. Because participants received weight-based dosing, data were collected by randomized study arm regardless of the actual dose received. Per local law, race and ethnicity data were not collected for participants located in France.
| Age, Continuous(years) | Ravulizumab | Placebo | Total |
|---|---|---|---|
| Mean | 71.1 ± 8.12 | 70.9 ± 8.43 | 71.0 ± 8.27 |
| Sex: Female, Male(Participants) | Ravulizumab | Placebo | Total |
|---|---|---|---|
| Female | 77 | 79 | 156 |
| Male | 201 | 198 | 399 |
| Race/Ethnicity, Customized(Participants) | Ravulizumab | Placebo | Total |
|---|---|---|---|
| Asian | 44 | 58 | 102 |
| Black or African American | 7 | 11 | 18 |
| White | 174 | 164 | 338 |
| Not Reported | 1 | 0 | 1 |
| Multiple Race | 47 | 37 | 84 |
| Other Than Specified | 2 | 3 | 5 |
| Not Collectable | 3 | 4 | 7 |
| Race/Ethnicity, Customized(Participants) | Ravulizumab | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 45 | 52 | 97 |
| Not Hispanic or Latino | 225 | 215 | 440 |
| Not Reported | 3 | 4 | 7 |
| Unknown | 2 | 2 | 4 |
| Not Collectable | 3 | 4 | 7 |
Showing the first 100 of 130 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Ran from Apr 2023 to primary completion in Oct 2025, 30 months.
Results were first posted in Oct 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ravulizumab
Renal Insufficiency, Chronic →
Alexion Pharmaceuticals, Inc. →